|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0830 AUD | 0.00% |
|
0.00% | -2.35% |
| 02/01 | FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate | MT |
| 02/01 | Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001 | RE |
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -13.37L | -17.08L | -62.12L | -76.73L | -1.66Cr | |||||
Depreciation & Amortization - CF | 3L | 3L | 3L | 1.64T | 44 | |||||
Depreciation & Amortization, Total | 3L | 3L | 3L | 1.64T | 44 | |||||
(Gain) Loss From Sale Of Asset | - | - | 180 | -12.27L | - | |||||
Asset Writedown & Restructuring Costs | - | 32.52T | 35.83L | 31.07L | - | |||||
Stock-Based Compensation (CF) | 2L | -46.34T | -10T | 4L | 5L | |||||
Other Operating Activities, Total | 45.89T | - | 5L | - | - | |||||
Change In Accounts Receivable | 55.73T | 56.63T | -40.9T | 1L | 16.99T | |||||
Change In Inventories | -2L | -34.92T | -4.22T | - | - | |||||
Change In Accounts Payable | 2.01T | 44.63T | 3L | 5L | 5L | |||||
Change in Other Net Operating Assets | -7.06T | 8.5T | -36.68T | -4L | 12.82L | |||||
Cash from Operations | -9L | -13.32L | -15.64L | -51.69L | -1.43Cr | |||||
Capital Expenditure | -1L | -43.38T | -34.76T | - | -1.54T | |||||
Divestitures | - | - | - | -2L | - | |||||
Sale (Purchase) of Intangible assets | -36.32T | - | -167 | - | - | |||||
Investment in Marketable and Equity Securities, Total | - | - | - | -10L | -20T | |||||
Cash from Investing | -1L | -43.38T | -34.93T | -11.65L | -21.54T | |||||
Long-Term Debt Issued, Total | - | 2L | - | - | - | |||||
Total Debt Issued | - | 2L | - | - | - | |||||
Long-Term Debt Repaid, Total | -3L | -2L | -4L | - | - | |||||
Total Debt Repaid | -3L | -2L | -4L | - | - | |||||
Issuance of Common Stock | 15.82L | 7L | 24L | 1.29Cr | 87.96L | |||||
Other Financing Activities, Total | -44.99T | - | -2L | 4L | -35T | |||||
Cash from Financing | 12.16L | 8L | 18.89L | 1.33Cr | 87.61L | |||||
Net Change in Cash | 1L | -6L | 3L | 70.08L | -55.53L | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 33.1T | 88.51T | 81.86T | - | - | |||||
Levered Free Cash Flow | -6L | -8L | -4L | -36.53L | -92.14L | |||||
Unlevered Free Cash Flow | -6L | -7L | -4L | -36.53L | -92.14L | |||||
Change In Net Working Capital | 85.76T | -74.19T | -13.83L | 4L | -9L | |||||
Net Debt Issued / Repaid | -3L | 52.49T | -4L | - | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















